ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

ATHA Athira Pharma Inc

2.04
0.00 (0.00%)
Pre Mercado
Última actualización: 03:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Athira Pharma Inc ATHA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 2.04 03:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.04
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
15/4/202406:00GLOBEAthira Pharma Appoints Javier San Martin, M.D., as Chief..
11/4/202406:00GLOBEAthira Pharma Announces Publication of Preclinical Data..
03/4/202406:00GLOBEAthira Pharma Announces Upcoming Poster Presentation at..
08/3/202406:00GLOBEAthira Pharma Presents Clinical and Preclinical Data..
22/2/202415:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202415:10EDGAR2Form 8-K - Current report
22/2/202415:05GLOBEAthira Pharma Reports Full Year 2023 Financial Results and..
16/2/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:40EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
08/2/202415:02GLOBEAthira Pharma Announces Publication in Frontiers in..
08/1/202415:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202406:11EDGAR2Form 8-K - Current report
08/1/202406:00GLOBEAthira Pharma Provides 2024 Clinical Pipeline Outlook and..
03/1/202406:00GLOBEAthira Pharma Completes Enrollment of Phase 2/3 LIFT-AD..
12/12/202306:00GLOBEAthira Pharma Announces Encouraging Results from SHAPE Phase..
29/11/202306:00GLOBEAthira Pharma to Participate in Sidoti December Small Cap..
28/11/202306:00GLOBEAthira Pharma Announces Upcoming Presentation at Motor..
15/11/202307:15GLOBEAthira Pharma Presents Preclinical Data Highlighting..
09/11/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:10EDGAR2Form 8-K - Current report
09/11/202315:05GLOBEAthira Pharma Reports Third Quarter 2023 Financial Results..
08/11/202306:00GLOBEAthira Pharma to Participate in Jefferies London Healthcare..
05/10/202315:30GLOBEAthira Pharma Presents Preclinical Data Further Supporting..
28/9/202306:00GLOBEAthira Pharma to Participate in Upcoming October Conferences
19/9/202306:00GLOBEAthira Pharma to Participate in the 2023 Cantor Fitzgerald..
10/8/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:10EDGAR2Form 8-K - Current report
10/8/202315:05GLOBEAthira Pharma Reports Second Quarter 2023 Financial Results..
17/7/202306:00GLOBEAthira Pharma Presents Phase 2 Clinical Data Correlating..
06/7/202306:00GLOBEAthira Pharma Announces Upcoming Presentations at the..
31/5/202306:00GLOBEAthira Pharma to Participate in Upcoming June Conferences
22/5/202306:00GLOBEAthira Pharma Appoints Andrew Gengos as Chief Financial..
11/5/202315:05GLOBEAthira Pharma Reports First Quarter 2023 Financial Results..
08/5/202306:00GLOBEAthira Pharma to Participate in Upcoming May Investor..

Su Consulta Reciente

Delayed Upgrade Clock